Site-specific bioconjugations with Biohaven’s MATETM technology: Application to therapeutic agents for pathogenic protein degradation

Abstract: Bioconjugations play an important role in next-generation therapeutic agents, as exemplified by antibody drug conjugates. New methodologies for site-specific bioconjugations allow for the design and manufacture of improved therapies with enhanced homogeneity, leading to a more consistent therapeutic profile. Biohaven’s Multimodal Antibody Therapy Enhancer (MATETM) allows for highly efficient and selective bioconjugations with ‘off-the-shelf’ therapeutic monoclonal antibodies (mAbs) and a range of cytotoxic and non-cytotoxic payloads. The design and application of the MATETM technology to ADCs and pathogenic protein degraders, including kilogram scale manufacture and green chemistry implications, will be discussed.